On May 13, the fifth annual meeting of the Drug Information As☆sociation (DIA) with the theme of "patient care and drug safety"★ was held in Beijing. Yin Li, deputy director of t↓he State Food and Drug Administration, said at the meeting: "The Chinese government £attaches great importance to drug safety and established the State Food and Drug Administration  in this institutional reform. The purpose is to optimize regulatory res​ources and strengthen system risk prevention and control.λ, Comprehensively strengthen food and drug supervision."

Yin Li pointed out that we will reform and improve the dεrug safety supervision mechanism, scientifically divide the central and locaαl drug supervision powers and responsibilities, content and procedures, and form a supervision sy✔stem with clear powers and responsibilities, reasonable division of labor✔, and legal protection; further strengthen the construction of the≠ drug supervision system and continue Improve risk monit♠oring, standard management, electronic supervision traceability, emergency management and ot₽her aspects; actively mobilize social forces to participate in su‌pervision, give better play to the comprehensive power of abnormal m¶echanism, industry self-discipline and social supervision to promot↕e social co-governance.

The first is to advocate the creation of new drugs and accelerate the reform of drug review. Vεigorously promote the construction of drug research platforms, encour‍age innovative development of new drugs, and strengthen the super‍vision of drug safety evaluation institutions and clinical trial bases. Intensify the÷ reform of the drug review system, optimize review resources, and improve r÷eview efficiency. Carry out quality consistency evaluation of generic drug s to improve the quality of basic drugs and commonly used clinical drugs. Promote the improveme×nt of drug standards and improve the level of drug safety.

The second is to strengthen the construction of drug laws and regulations and dr ug supervision infrastructure, strictly enforce the law, and admini♥ster according to law. Promote the implementation of new GMP and new GSP, and gradually >transform the industrial chain into a responsibility chain. We should attach importance to and st₽rengthen drug inspection, reasonably plan the strength and tasks of inspection equipment at thαe national, provincial and municipal levels, and strengthen the ability of rapid screening a♣t the grass-roots level.

Third, improve the risk early warning and control management mechanism. Strengthen the constructi"on of a strong integrity system, establish a reasonablπe system to manage people, promote the construction of →drug electronic supervision, and gradually realize the real-ti&me monitoring and management of drug quality and flow tr₽aceability. Strengthen the capacity building of adverse drug reaction monitoring,← and actively carry out post-marketing evaluation of drugs. In view of the key areas and₩ weak links, strengthen the on-the-job training of professional and technical personnel and< calendar personnel.

Fourth, crack down on the manufacture and sale of counterfeit drugs to protect the pu♠blic interest. Special actions will be carried out to crack down on illegal and illegal use of adv✔ertising, "black dens" counterfeiting and Internet sales. Build authoritative and co•nvenient drug safety information platform for public inquiry. Strengthen the community-ori₹ented news release and popular science propaganda.